Trial intelligence / Profile preview

Pharmacokinetic Study of Granexin Gel in Venous Leg Ulcers

NCT02652572Phase 1Completed

Sponsor
Xequel Bio
Start
Sep 2015
Primary completion
Dec 2017
Modality
Small Molecules
Countries
1
01

Overview

Phase 1, open-label, single-arm trial of zifogaptide in venous leg ulcer (VLU), sponsored by Xequel Bio. Primary endpoint: Measurement of aCT1 peptide levels in blood at Day 7. Started Sep 2015; status: completed.

02

Drugs

zifogaptide
03

Conditions

venous leg ulcer (VLU)

Beyond the preview

Go deeper on NCT02652572.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02652572.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call